Assessment of the Efficiency of Specialization Therapies of Breast Cancer by Evaluation of Oxidative Stress

Abstract

Background: Breast cancer is one of the leading causes of cancer related death, when it is the second most common cancer in women after lung, when it constitutes 23% of all cancer cases in women, moreover it presents the first in global mortality (18.6%) of cancer According to the latest statistics, breast cancer ranks the first number (2,088,849 new cases) of recorded cases worldwide, annually. Breast cancer is a significant and common disease that has a negative effect on women health, and deaths, 626,679 cases). When an imbalance between free radical production and detoxification occurs, ROS production may overwhelm antioxidant defenses, leading to the generation of a noxious condition called Oxidative Stress and overall to the impairment of the cellular functions. Subjects: Seventy four females were included in the current study, they were classified into three groups depending on their health and the type of tumor suffered by patients. The first included 25 females with malignant breast tumors, the second group included 24 women who had benign breast tumors, and the last group included 25 women who appeared to be healthy. Results: All of NO and MDA showed significant statistical significant increase (p=0.000), in contrast to SOD which illustrated significant decrease (p=0.000) in patients with breast cancer when compared with benign tumor patients as well as healthy controls group. The current study recorded an increase in the level of MDA and SOD concentrations in all samples diagnosed as breast cancer patients, which make the sensitivity of this parameters up to 100%, while the sensitivity percentage of NO reached to 96% . When the levels of studied parameters were experiential during the chemotherapy stage, a gradual decrease of the NO was observed to be proportional to the number of doses received by the patients, from other side; all of MDA and SOD showed significant increase agreed with progression of chemotherapy stages.